Report Date: Tuesday, August 4, 2026 (after market close) | Event: Q2 2026 Earnings Call
IFF heads into this print off a strong Q1 that beat expectations and a stock that has been volatile but resilient — currently trading around $80.60, comfortably above its May lows (~$70) but still short of its post-earnings spike to ~$83 in early May and early July. Consensus sentiment has turned more constructive over the summer: Morgan Stanley raised its price target on IFF to $95 from $93 and kept an Overweight rating on the shares in early July, and the stock currently carries a Strong Buy/Buy consensus with average price targets in the low-to-mid $90s, implying meaningful upside from current levels.
But the bigger story for 2026 isn't the quarterly print itself — it's the ongoing portfolio transformation, which has accelerated dramatically since Q1 results were reported in May.
IFF's Q1 was a "beat and reaffirm" quarter: - Reported net sales of $2.74 billion (down 4% reported, +3% comparable currency-neutral), with the company noting broad based growth across all businesses in the release. - Adjusted operating EBITDA of $568 million, +8% comparable currency-neutral, with margin at 20.7% — management called this our highest EBITDA margin since the second quarter of 2022 on the call. - Adjusted EPS ex-amortization of $1.25, comfortably ahead of the roughly $1.08 consensus at the time. - Free cash flow of $92 million, up $144 million year-over-year, and net debt/credit-adjusted EBITDA improved to 2.5x. - Management reaffirmed full-year 2026 guidance: sales of $10.5–10.8 billion (1–4% comparable CC growth) and adjusted operating EBITDA of $2.05–2.15 billion (3–8% comparable CC growth).
Crucially, management already told investors what to expect for Q2 — this is the single most important context for tomorrow's print.
On the Q1 call, CFO Michael DeVeau was unusually direct that Q2 EBITDA would be sequentially lower than Q1's $568 million, driven by three factors: 1. Moderating growth versus Q1's unusually strong volume performance (management cautioned Taste's 18% currency-neutral EBITDA growth in Q1 specifically "will abate" and "normalize" going forward). 2. Unfavorable price-to-input-cost timing — rising energy/logistics/raw material costs (tied to the Middle East conflict and higher Brent crude) hitting before pricing surcharges are fully implemented with customers. 3. Fine Fragrance softness tied to the Middle East conflict — both slower end-market demand and temporary customer supply-chain/packaging disruptions into the region, concentrated in the Scent segment.
Management framed this as a timing issue, not a guidance cut: pricing actions should build through the year and inflationary pressure should "gradually ease through the back half," supporting the reaffirmed full-year range. The key question for tomorrow is whether Q2 actual results landed in line with, better, or worse than that guardrail — and whether the pricing/cost offset is tracking on schedule.
Since the Q1 call, IFF announced the transaction the market had been waiting for. On May 29, 2026, IFF announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners... in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. IFF is retaining an approximately 10% minority equity interest in the business, or approximately $200 million, allowing continued upside participation.
Key deal mechanics investors should have top of mind heading into the call: - Expected net cash proceeds to IFF of ~$3.8 billion, earmarked for debt reduction, share buybacks, and reinvestment in Taste, Scent, and Health & Biosciences. - The transaction is expected to close by the end of the second quarter of 2027, subject to HSR and other regulatory approvals — meaning Food Ingredients remains fully consolidated in IFF's numbers (including tomorrow's Q2 print) for some time yet. - Management has flagged near-term dilution: the deal is expected to be dilutive to adjusted EPS in the first 12 months post-close, before cost/capital-deployment benefits are realized, though IFF has said it has a plan to address stranded overhead costs. - This is IFF's 13th divestiture since 2021, part of a multi-year simplification effort that has now generated close to $10 billion in gross proceeds.
Layered on top, on July 20, 2026, IFF announced a smaller bolt-on divestiture — its portfolio of botanical extracts, vitamins and minerals, and food enhancement activities to SuanNutra (a Carbyne Equity Partners company), a business that generated approximately $170 million in revenues in 2025. It's a smaller deal, but it confirms management is continuing to prune the portfolio even as the larger CVC transaction is pending.
What to listen for tomorrow: an update on CVC deal regulatory progress/timeline, confirmation guidance is unchanged (or reset) given the growing divestiture perimeter, and color on stranded-cost mitigation plans and capital-deployment priorities (buybacks vs. debt paydown vs. bolt-on M&A) once proceeds arrive.
Wall Street has trimmed numbers modestly heading into the print: - Zacks consensus: sales of ~$2.68 billion (a 2.9% year-over-year decline) and EPS of ~$1.14 (down slightly y/y), with estimates moved down in the past 60 days. - Other trackers show slightly lower estimates around $1.07 EPS on ~$2.62 billion revenue. - Zacks' quantitative model currently points to a likely beat, citing a positive Earnings ESP, though the setup is less lopsided than Q1's. - IFF has beaten consensus EPS in three of the last four quarters, with an average beat near 4%.
The revenue decline embedded in estimates reflects the ongoing divestiture drag (management guided ~5% adverse impact to sales/EBITDA growth from divestitures in 2026) as well as the FX/input-cost dynamics flagged for Q2 specifically.
IFF ended Q1 with net debt/credit-adjusted EBITDA of 2.5x, down meaningfully from prior-year levels (total debt reduced by more than $3 billion year-over-year), and has an active buyback program originally sized to offset dilution. With ~$3.8 billion of prospective CVC proceeds still ahead, expect questions on the cadence of debt paydown versus more aggressive buybacks, and any incremental M&A appetite (management has mentioned ventures like Alpha Bio as examples of where it might deploy capital).
This is less a "beat/miss the number" quarter and more a checkpoint on execution against a guidance path management explicitly pre-warned would dip sequentially, set against the backdrop of a transformative divestiture that is reshaping the company's earnings base, leverage, and strategic focus. Key things to watch on tomorrow's call: